A case report of a 15-year-old adolescent male who developed a hypersensitivity reaction to a parenteral nutrition (PN) solution containing multivitamins (MVI) is presented. Within 30 minutes after initiation of PN and lipids, the patient developed a total-body pruritic urticarial rash that resolved after discontinuation of the infusions and administration of diphenhydramine. Rechallenge with the same PN solution excluding heparin, as well as lipids, resulted in a similar urticarial reaction that also resolved within 30 minutes after discontinuation of the infusions and administration of diphenhydramine. Another rechallenge with a solution containing dextrose and amino acids at the same concentrations contained in the original PN solution did not elicit an allergic reaction, whereas addition of MVI to the dextrose and amino acids resulted in a similar allergic reaction 20 minutes after the start of the infusion. It was determined that the MVI component of the PN was the most likely causative agent of this patient's urticarial reaction.
BackgroundIn 2014, the AAP updated guidelines for administration of palivizumab in children at high risk of respiratory syncytial virus (RSV) disease. The updated guidelines defined high risk patient populations and recommended that eligible inpatients not receive monthly palivizumab prophylaxis but may receive a dose 24–72 hours prior to discharge. In a freestanding children’s hospital, the ASP developed a protocol that ensured compliance with the adoption of these guidelines through prospective audit of all palivizumab orders prior to medication dispensing. Review of 2 seasons of palivizumab inpatient protocol dosing was compared with historical baseline drug utilization.MethodsAll palivizumab orders required an indication that was reviewed by a pharmacist who confirmed the patient’s medical condition(s) and eligibility prior to medication dispensing. The pharmacist verbally reconciled any discrepancies with the ordering provider and if patient did not meet AAP guideline criteria, two members of the ASP reviewed the order and patient’s medical record to determine inpatient eligibility for palivizumab administration. Two RSV seasons of palivizumab inpatient dosing were compared with the baseline year prior to protocol adoption to analyze impact of the protocol on direct costs of palivizumab to the organization.ResultsTwo hundred and seventy-seven inpatient doses of palivizumab were reviewed from November 1, 2014 to April 30, 2017. After implementation of the palivizumab protocol, the number of doses administered decreased each RSV season (see Figure 1). This resulted in a decrease in drug expenditures in each of the post implementation seasons (see Figure 2). The ASP reviewed orders for 10 patients during the 2015–2016 season and 16 patients during the 2016–2017 season for unapproved indications. Hospital-acquired RSV infections remained stable after protocol implementation and isolation recommendations were unchanged.ConclusionIn a freestanding children’s hospital, an ASP driven protocol reduced palivizumab administration to inpatients in keeping with AAP guidelines while reducing direct pharmacy costs and without an increase in hospital-acquired RSV infections during the evaluation period.Disclosures
All authors: No reported disclosures.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.